Ipamorelin: the selective GH secretagogue

TL;DR

• A selective agonist at the ghrelin receptor on the pituitary, prompting release of your own stored growth hormone.
• Selectivity is the whole appeal: minimal cortisol or prolactin co-stimulation, unlike older secretagogues such as GHRP-6 and hexarelin.
• It amplifies a pulse rather than starting one, which is why it is paired with a GHRH analogue working on a separate receptor.
• GH elevation is demonstrated; recomposition is not. The leap from "raises GH" to "changes your physique" outruns the human trials.
• Cancer history is a screening question: raising IGF-1 carries a theoretical concern wherever cell proliferation matters.
• Not FDA-approved, sold "research use only," WADA-prohibited. Blood sugar warrants monitoring, though it is milder here than with MK-677.
• A September 2026 review of 565 studies put ipamorelin in the same place this page already did. More than two-thirds of the literature across six marketed compounds was animal-only, the human work generally low quality, and no studies were identified showing significant clinical benefit for musculoskeletal conditions. That describes where research money has gone, not a test of the compound; the GH-pulse elevation covered below is separate, real, and was not what the review was measuring.

Ipamorelin is the "clean" growth-hormone peptide: it nudges your pituitary to release GH without dragging up cortisol and prolactin the way older secretagogues did. That selectivity is its whole appeal. Here's what it actually does, why it's almost always paired with CJC-1295, and where the evidence really sits.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed. Ipamorelin is investigational and not FDA-approved. Raising GH/IGF-1 is a cancer-history screening matter.

Updated September 2026: adds the UCLA Health review of 565 studies published on 8 September 2026 in The American Journal of Sports Medicine, which assessed ipamorelin among six widely marketed compounds and found the literature overwhelmingly animal-only, the human research generally low quality, and no studies demonstrating significant clinical benefit for musculoskeletal conditions, together with its safety and product-quality findings.

---

If you've read the growth-hormone peptides guide, you know the field splits into two families. Ipamorelin sits firmly in the "amplifier" camp: a ghrelin mimetic that boosts the size of your natural GH pulse. What made it the default choice over older options (GHRP-6, hexarelin) is one word: selectivity. It raises GH cleanly, without the cortisol and prolactin baggage. Here's the honest picture.

What ipamorelin is

Ipamorelin is a synthetic peptide that acts as a selective agonist at the growth-hormone secretagogue receptor (the ghrelin receptor) on the pituitary. Activating that receptor prompts a release of your own stored growth hormone. Unlike its predecessors, at the exposures studied it produces minimal cortisol or prolactin co-stimulation, which matters, because cortisol is catabolic and immunosuppressive, exactly the opposite of what someone pursuing recovery or body composition wants. That "clean pulse" is the reason ipamorelin became the go-to GHRP.

Pulse trigger vs pulse amplifier

The distinction that makes ipamorelin make sense: it doesn't start the GH pulse, it amplifies one. GHRH analogs (sermorelin, CJC-1295, tesamorelin) mimic the hypothalamic signal that triggers a pulse; ipamorelin works on a different receptor to make the resulting release bigger. Two different levers on the same machine, which is precisely why they're combined.

Why ipamorelin + CJC-1295 is the classic pairing

Because a GHRH analog and a GHRP act on separate receptor systems, using them together produces a synergistic GH release: meaningfully greater than either alone. CJC-1295 sets up a stronger, more sustained GHRH signal; ipamorelin amplifies the pulse on top of it, cleanly. That complementary logic, not marketing, is why CJC-1295 + ipamorelin is the most common GH-axis pairing you'll see. The specifics of how they're combined are protocol- and person-dependent, and belong with a clinician.

What the evidence actually supports

Here's where honesty matters. Ipamorelin has favorable safety data and demonstrated GH-pulse elevation in clinical studies. That part is real. What it does not have is a body of large human trials showing the downstream outcomes people buy it for: muscle gain, fat loss, anti-aging. Those are extrapolations from "it raises GH" to "it will recomposition your body," and the human evidence for the second step is thin. So the accurate framing: a well-tolerated, selective secretagogue that reliably raises GH in studies, with outcome claims that outrun the trials. Promising and relatively clean, not proven to transform physique.

The September 2026 review, and where ipamorelin sits in it

That assessment now has an external check. On 8 September 2026, UCLA Health published a review in The American Journal of Sports Medicine covering 565 studies across six widely marketed compounds: BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. It is the most complete description of this literature assembled to date, and ipamorelin is one of the six.

What it found, stated as the reviewers stated it:

• More than two-thirds of the 565 studies were animal-only.
• The human research was generally of low quality: small, short, methodologically limited.
• Outside orthopaedic indications, the human work showed modest improvements at best.
• The reviewers did not identify studies demonstrating significant clinical benefit for musculoskeletal conditions.
• On safety, they noted that a trial of MK-677 was stopped over congestive heart failure risk. That is a finding about that compound, not about ipamorelin, but it belongs on this page because the two are constantly discussed together and are not equivalent on safety.
• On product quality, they warned that unapproved products of this kind are unregulated and may contain undisclosed or dangerous substances.

Their conclusion was that marketing claims run far ahead of the science. Read it for what it is: an assessment of the literature as it stood in September 2026, across a category, by named reviewers in a named journal. It is not a finding that ipamorelin does nothing, and it should not be reported as one: the GH-pulse elevation described above is real and was not what the review was testing. What it does is locate the downstream claim precisely: if you are being sold ipamorelin on recovery or body-composition outcomes, the human studies supporting that have not been run, which is a statement about what has been funded rather than a result showing it fails. Ipamorelin remains investigational.

Safety, monitoring, and status

• GH/IGF-1 elevation. The central caution for the whole class: raising IGF-1 has a theoretical concern wherever cell proliferation matters, making a cancer history a screening question before starting.
• Blood sugar. GH secretagogues can nudge insulin sensitivity; worth monitoring, though ipamorelin is milder here than MK-677.
• Common, usually mild effects. Transient head-rush/flushing, water retention, appetite changes.
• Regulatory status. Not FDA-approved; sold "for research use only," and on the WADA prohibited list for athletes. This is why supervised use with verified product matters: the general peptide side-effect cautions all apply.

The bottom line: where to start

Ipamorelin is the cleanest of the GH secretagogues: selective, well-tolerated, reliably GH-raising in studies, and mechanistically sensible when paired with a GHRH analog. It's also investigational, research-only, and carries the class's GH/IGF-1 and blood-sugar cautions, so it belongs in supervised care with baseline and follow-up bloodwork, not a self-sourced stack. Used that way, it's a reasonable GH-axis option; used blind off a grey-market vial, it's an IGF-1 experiment with no screening.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Ipamorelin.

Frequently asked questions

Does ipamorelin build muscle? It reliably raises your own GH in studies, but large human trials showing it directly builds muscle or strips fat are lacking. The "it raises GH, therefore it recompositions you" leap runs ahead of the evidence. A UCLA Health review of 565 studies published on 8 September 2026 in The American Journal of Sports Medicine (ipamorelin among the six compounds assessed) found more than two-thirds of that literature animal-only, the human work generally low quality, and no studies demonstrating significant clinical benefit for musculoskeletal conditions.

What did the 565-study review actually say about ipamorelin? It described the shape of the evidence rather than testing the compound. Across the six compounds it covered, more than two-thirds of the studies were animal-only, the human research was generally low quality with modest improvements at best outside orthopaedic indications, and it identified no studies showing significant clinical benefit for musculoskeletal conditions. It also flagged that a trial of MK-677 (a different compound) was stopped over congestive heart failure risk, and warned that unapproved products of this kind are unregulated and may contain undisclosed or dangerous substances. Its conclusion was that marketing claims run far ahead of the science.

Why is ipamorelin paired with CJC-1295? They act on different receptors: CJC-1295 (a GHRH analog) triggers the pulse, ipamorelin (a GHRP) amplifies it. Together they produce a synergistic GH release greater than either alone.

Is ipamorelin safe long-term? Short-term safety looks favorable and it's "cleaner" than older GHRPs, but long-term human data is limited, and the GH/IGF-1 and blood-sugar cautions mean it should be monitored. Cancer history is a screening question.

Ipamorelin vs sermorelin: what's the difference? Different families: sermorelin is a GHRH analog (pulse trigger); ipamorelin is a ghrelin mimetic (pulse amplifier). They're often combined rather than compared. Full GHRH comparison here.

Related reading

• How growth-hormone peptides work: the GH/IGF-1 axis · Why CJC-1295 and ipamorelin are paired · CJC-1295 with or without DAC · Sermorelin vs CJC-1295 vs tesamorelin · Tesamorelin explained · GHRP-2, GHRP-6 and hexarelin: what ipamorelin was designed to replace
• Part of The Complete Guide to Growth-Hormone Peptides

---

Educational content, not medical advice. Ipamorelin is investigational, not FDA-approved, and physician-directed; it raises GH/IGF-1 (a cancer-history screening matter) and can affect blood sugar. WADA-prohibited. SEA-market claims are subject to MAB requirements.

References

• Ipamorelin: selective GH-secretagogue-receptor agonism with minimal cortisol/prolactin co-stimulation; GH-pulse elevation and safety data in clinical studies. · GHRH-analog + GHRP synergy (separate receptor systems). · WADA Prohibited List (S2). · **UCLA Health review of 565 studies across BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu, published 8 September 2026 in The American Journal of Sports Medicine:** more than two-thirds of studies animal-only; human research generally low quality; modest improvements at best for non-orthopaedic indications; no studies identified demonstrating significant clinical benefit for musculoskeletal conditions; a trial of MK-677 halted over congestive heart failure risk; a declared financial interest held by a group behind one of the largest BPC-157 studies; warning that unapproved products are unregulated and may contain undisclosed or dangerous substances; conclusion that marketing claims run far ahead of the science.